Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
entities : Astrazeneca plc symbols : Iphyf save search
Hairy Cell Leukemia Therapeutics Market Size to Grow by USD 177.85 million, Majority of Growth to Originate from North America - Technavio
Published: 2022-08-22 (Crawled : 07:00) - prnewswire.com
AZNCF | $140.15 3.58% -4.19% 560
|
Health Technology
|
| O: 2.39%
H: 1.09%
C: 1.09%
VTRS | $11.1 -0.18% -0.23% 4.7M
|
Health Technology
|
| O: -0.66%
H: 0.1%
C: -1.43%
ABBV | $164.25 1.05% 0.26% 3M
|
Health Technology
|
| O: 0.08%
H: 0.49%
C: -1.15%
AZN | $68.53 0.39% 0.39% 3.2M
|
Health Technology
|
| O: 0.49%
H: 1.11%
C: -0.39%
AMGN | $264.07 -0.59% -0.59% 1.6M
|
Health Technology
|
| O: -0.35%
H: 0.5%
C: -1.23%
america leukemia therapeutics growth market
Innate Pharma Provides Update on AstraZeneca-Sponsored INTERLINK-1 Phase 3 Study
Published: 2022-08-01 (Crawled : 10:00) - biospace.com/
IPHYF | $2.65 104.6% 300
|
Health Technology
|
| O: -14.87%
H: 4.09%
C: 4.09%
SNYNF | News | $92.7 0.63% -2.18% 1.4K
|
Health Technology
|
| O: -3.9%
H: 0.0%
C: 0.0%
NVO | News | $124.53 0.88% 0.19% 2.5M
|
Health Technology
|
| O: -0.21%
H: 0.41%
C: -0.73%
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
|
| O: -1.92%
H: 0.0%
C: 0.0%
IPHA | $2.41 -6.95% -10.21% 16K
|
Health Technology
|
| O: -11.25%
H: 0.0%
C: -1.06%
AZN | $68.53 0.39% 0.39% 3.2M
|
Health Technology
|
| O: 0.44%
H: 0.53%
C: -1.31%
pharma update study
Innate Pharma Announces IPH5201 Phase 2 Study in Lung Cancer
Published: 2022-06-03 (Crawled : 08:00) - biospace.com/
IPHYF | $2.65 104.6% 300
|
Health Technology
|
| O: 1.65%
H: 0.0%
C: -0.32%
SNYNF | News | $92.7 0.63% -2.18% 1.4K
|
Health Technology
|
| O: -0.94%
H: 0.0%
C: 0.0%
NVO | News | $124.53 0.88% 0.19% 2.5M
|
Health Technology
|
| O: 0.65%
H: 0.63%
C: 0.16%
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
|
| O: -0.09%
H: 0.0%
C: 0.0%
IPHA | $2.41 -6.95% -10.21% 16K
|
Health Technology
|
| O: 2.96%
H: 0.98%
C: -1.15%
AZN | $68.53 0.39% 0.39% 3.2M
|
Health Technology
|
| O: -0.56%
H: 0.82%
C: -0.64%
iph5201 pharma cancer phase 2
Innate Pharma: First Patient Dosed in Monalizumab Phase 3 Lung Cancer Clinical Trial Triggers $50M Payment From AstraZeneca
Published: 2022-04-29 (Crawled : 11:00) - biospace.com/
SNYNF | News | $92.7 0.63% -2.18% 1.4K
|
Health Technology
|
| O: 0.48%
H: 0.24%
C: 0.24%
NVO | News | $124.53 0.88% 0.19% 2.5M
|
Health Technology
|
| O: 5.98%
H: 1.44%
C: -0.42%
SNY | News | $46.11 0.68% 0.7% 3.5M
|
Health Technology
|
| O: 1.93%
H: 0.0%
C: 0.0%
IPHA | $2.41 -6.95% -10.21% 16K
|
Health Technology
|
| O: 11.11%
H: 3.67%
C: -4.33%
AZN | $68.53 0.39% 0.39% 3.2M
|
Health Technology
|
| O: 0.53%
H: 2.37%
C: 0.26%
trial payment cancer phase 3
Gainers vs Losers
| 57% | 43% |
Top 10 Gainers
INVO | $1.82 139.47% 56.82% 220M
|
Health Technology
SINT | $0.0373 62.88% 37.26% 460M
|
Health Technology
WISA 4 | $9.25 51.64% 34.27% 64M
|
Electronic Technology
EDBL | News | $6.66 46.37% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 600K
|
Manufacturing
TCON | $2.29 33.92% 26.61% 1.8M
|
Health Technology
TIRX | $0.4848 7.49% 24.58% 5.9M
|
SRFM 4 | $0.3859 -12.3% 23.84% 660K
|
n/a
CTM | $0.2201 -2.31% 22.67% 48K
|
n/a
VNDA | News | $5.24 29.38% 22.56% 24M
|
Health Technology
Your saved searches
Save your searches and get alerts when important news are released.